Pioneering CiQUS Research Enables Safer Light-Activated Drugs

24/04/2026

Effective medicine often comes with risks. Many chemical compounds powerful enough to halt disease or shrink tumors can also harm healthy tissue long before reaching their target. How, then, can we ensure these drugs arrive safely at their destination without causing collateral damage? The answer lies in a biological camouflage strategy: prodrugs. This concept is at the heart of new research led by Professor José Luis Mascareñas at CiQUS, with Mauro Mato as first author, alongside Adrian Rivas, Alba Casas, and María Tomás.

According to Mascareñas, 10–15% of hospital-administered drugs are already used as prodrugs—compounds that activate inside the body, typically via enzymes. “This reduces side effects and improves solubility and transport,” he explains.

A Major Limitation—and a Novel Solution

However, traditional prodrug approaches lack external control over when and where the drug activates. While light has been used to trigger prodrugs externally, it often requires high-energy (and potentially harmful) ultraviolet radiation. The CiQUS team has now proposed an innovative alternative: dual activation using photosensitizers and visible light. “The drug only activates where both elements converge, enabling far more precise control,” says Mascareñas. But what makes this approach truly groundbreaking?

A Conceptual Shift in Drug Design

The team’s work, published in the Journal of the American Chemical Society and featured in a Nature Synthesis editorial, introduces a paradigm shift. Previously, light-activated prodrugs required an amino group—a nitrogen atom protruding from the molecule. “Without it, you couldn’t modify the compound into a prodrug,” notes Mascareñas.

The breakthrough? Thianthrenium salts—sulfur-containing compounds—eliminate this requirement. “We’re no longer limited to amino groups; we can act directly on the carbon backbone of molecules,” he explains. Since many drugs are carbon-based, this technique dramatically expands the range of compounds that can be safely deactivated and reactivated on demand.

Pioneering Research with Radical Implications

The study demonstrates a novel way to activate prodrugs using light-driven chemical reactions that generate controlled free radicals—molecules often associated with damage, but here harnessed for good. “We’ve shown that we can produce benign radicals tailored to living systems, with precise spatial and temporal control,” Mascareñas highlights. This opens new avenues at the intersection of chemistry and biomedicine.

Medical Applications on the Horizon

As a proof of concept, the team tested an antifungal application. Without modification, such potent treatments could harm healthy cells before reaching the infection site. By pre-treating the drug with thianthrenium salts, it remains inactive until exposed to visible light at the target area. “This may not be the highest-impact application, but it’s a simple demonstration that the method works,” Mascareñas clarifies.

The most promising uses? Cancer treatments like melanoma, skin diseases, and ocular conditions, where light can be easily directed. “The compound circulates harmlessly throughout the body and only activates where light is applied—such as the eye,” he adds.

A Foundation for Future Therapies

While still in the conceptual phase and not yet tested in animals, this research lays critical groundwork. “Our goal isn’t to deliver immediate patient solutions, but to expand the reservoir of knowledge,” Mascareñas emphasizes. “This knowledge can be built upon by us or others worldwide, leading to applications we haven’t even imagined.”

From Galicia, this discovery doubles the impact: it introduces a new way to use radicals in living systems and proposes an innovative strategy for designing safer, more precise prodrugs—potentially reshaping the future of targeted therapies.

By Andrea Veiga, GCiencia.

Reference: Photoredox Unmasking of Aromatic C–H Bonds in Living Environments Enabled by Thianthrenium Salts (publicado en Journal of the American Chemical Society).

 

Left: Control sample showing normal fungal growth in the presence of the thianthrenium-containing prodrug. Right: Fungal growth halts after treatment with red light and a photocatalyst | Image: MetBioCat 

 

The CiQUS holds the CIGUS recognition by the Xunta de Galicia, that accredits the quality and impact of its research, and receives financial support from the European Union through the Galicia FEDER Program 2021-2027.